Advances in science are changing how we fight respiratory infections. Introducing Pfizer’s research study for an investigational combination vaccine that may protect against COVID-19 and RSV in one convenient shot.
SARS-CoV-2 (the virus that causes COVID-19) and respiratory syncytial virus (RSV) are common respiratory viruses. These viruses often spread at the same time as the flu virus. They cause similar symptoms like cough, fever, and sore throat. Millions of people get sick from these viruses each year, and they can be life-threatening for many people.
Pfizer is committed to developing vaccines that provide protection against serious respiratory infections. We are now developing a combination vaccine for COVID-19 and RSV. A single vaccine has the potential to protect more people against infection from both viruses with one convenient injection.
This study will evaluate if the investigational combination vaccine is safe and can help the body produce antibodies to fight COVID-19 and RSV when given alone or at the same time as a flu shot.
This research study is enrolling adults who:
- Are [at least 65] years old
- Are generally healthy or have stable chronic conditions
- Have not been diagnosed with COVID-19, RSV, or flu in the last [four months]
- Have not received a flu vaccine in the last [four months]
- Have received [at least three] prior doses of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna), and the last dose was a bivalent vaccine*
* In the U.S., all COVID-19 vaccine doses administered after September 1, 2022 are considered bivalent.
There will be other study requirements that the study team will discuss with you.
This study will last for about [six months] and includes [at least three] study visits. Participants will receive two or three study vaccine injections at the first study visit. There is no cost to participate, and reimbursement for any study-related expenses will be provided.
Ready to learn more?
Contact the study team: